tirzepatide weight loss injection vs. Semaglutide for Tirzepatide Weight Loss Injections &

The efficacy of IDegLira (Insulin Degludec/Liraglutide combination) in adults with type 2 diabetes inadequately controlled with a GLP-1 receptor agonist and oral therapy: DUAL III randomized clinical trial

Scenario 1: significant weight loss (50 or more pounds to lose) Starting point: BMI 35+, 50 to 100+ pounds above healthy weight range

Available at: Last accessed: 16 March 2026

Compounded semaglutide is $189/mo month-to-month, or from $149/mo on the 6-month plan and is HSA/FSA eligible, making treatment affordable and accessible regardless of insurance status

Typically, GI side effects of GLP-1s such as nausea and vomiting are dose-dependent, mild-to-moderate in severity and occur mostly during initiation of therapy and up-titration

Focus: Improving formulations, patient access, and expanding indications